News Focus
News Focus
Followers 6
Posts 565
Boards Moderated 0
Alias Born 07/12/2002

Re: Zeev Hed post# 160131

Saturday, 10/11/2003 5:18:21 PM

Saturday, October 11, 2003 5:18:21 PM

Post# of 704047
In edit, this is from the 2002 10K:

"Cross License between VISX and Bausch & Lomb. In January 2001, VISX and Bausch & Lomb signed an agreement
whereby we licensed our patents relating to refractive excimer lasers to Bausch & Lomb. As consideration, Bausch &
Lomb licensed its patents relating to refractive excimer lasers to us and will pay us a royalty for each procedure
performed in the United States using Bausch & Lomb’s refractive excimer laser. All pending disputes and litigation
between the two companies were also settled at that time."

http://media.corporate-ir.net/media_files/irol/95/95691/reports/200210K.pdf

Understood. However, (1) price is already $500/eye in many instances and will fall rapidly going forward - the profit margin in this simple procedure is insane (PS, I've had it done myself); (2) as the procedure will shortly be available for farsightedness as well, the market will exceed 150 mm; (3) like INTC with CPUs, EYE gets a flat per-eye royalty regardless of procedure cost, so as prices go down and procedures go up, EYE's business model shows strength (just as INTC sells more CPUs as DELL prices decline); (4) to the best of my knowledge, EYE gets a royalty on procedures performed on even their competitor's machines as the EYE patents are very broad (not positive about this, as the case settlements were confidential).

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today